Medicago reaches agreement with Canadian Government to locally produce and supply to Canada 76 million doses of its adjuvanted COVID-19 vaccine
Date Closed
October 23, 2020
Lead Office
Québec City
On October 23, 2020, Medicago reached an agreement with the Government of Canada to supply up to 76 million doses of its COVID-19 vaccine candidate, pending approval from Health Canada. The Canadian Government also pledged funding support to Medicago, for its vaccine research and development, and for the construction of its Quebec City manufacturing facility.
The vaccine is currently undergoing clinical trials. This agreement represents the first COVID-19 vaccine supply contract entered into by the government with a Canadian-based company for a vaccine being developed in Canada.
Medicago is a biopharmaceutical company headquartered in Quebec City focused on plant-based technologies and medical remedies.
McCarthy Tétrault advised Medicago with a team led by Philippe Leclerc that included Veronique Wattiez-Larose.
